FRA
LKFT

Front Row Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Front Row Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-32
Closed -$2K – 959
2021
Q1 		$2K Sell
32
-7
-18% -$645 ﹤0.01% 860
2020
Q4 		$4K Buy
39
+6
+18% +$734 ﹤0.01% 728
2020
Q3 		$4K Buy
+33
New +$5.5K ﹤0.01% 723

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Front Row Advisors's LKFT Position: Q2 2021 in Review

Front Row Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2021, closing a stake of 32 shares — an estimated $2K sold.

Front Row Advisors first reported a position in LKFT in Q3 2020 and held it in 3 quarters. The position peaked at $4K in Q4 2020. 108 funds tracked by Wall St. Rank hold LKFT as of Q2 2021.

  • Front Row Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • Front Row Advisors sold 32 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2021, an estimated $2K.
  • Front Row Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2020 and held it in 3 quarters.
  • Front Row Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $4K in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2021.

Based on Front Row Advisors's 13F filing for Q2 2021, filed 23 Aug 2021.